(PSYCHIATRIC TIMES) - "The age of the brain" has focused considerable intellectual and financial resources on achieving better understanding of the neurobiologic functioning of the brain in health and disease, in the hope of enhancing treatment for mental disorders. As part of this effort, psychiatry residencies de-emphasized psychotherapy education. Leaders of academic departments came to prefer faculty with credentials and experience that aligned the department of psychiatry with the focus on the age of the brain.
Psychotherapy training dwindled in many but not all residency training programs and the shift toward biologic preeminence meant psychotherapy nearly became lost as part of the skill set of many practicing psychiatrists.1 Some questioned whether psychotherapy, where it was indicated, ought to be provided in split treatments, with psychologists or social workers providing therapy at presumably lower costs than psychiatrists, while psychiatrists principally provided psychopharmacologic treatment.
Concurrent with the age of the brain came the impact of a transformation in funding for behavioral health treatments in the form of managed care. Managed care is part of an overall zeitgeist of resource limitation that affects today's world in such geopolitical arenas as global warming, depletion of fossil fuels, and loss of biodiversity. As such, managed care operates with the same moral imperative as the environmental movement, but it has often been associated with draconian limitations of care and with a clear preference for psychopharmacology over psychotherapy.2
The importance of psychotherapy was initially de-emphasized in the age of the brain and the era of managed care. Over time, however, several developments contributed to a significant resurgence of interest in psychotherapy. These include research findings suggesting that psychotherapy causes changes in the brain and is a highly effective treatment for a range of disorders. Furthermore, the leadership of the American Psychiatric Association (APA) and of the Residency Review Committee (RRC) became concerned about the potential loss of psychotherapy as part of the identity, skill set, and training of psychiatrists and took appropriate actions to reverse this trend.
Important contributions from a new generation of researchers suggest that psychotherapy is an effective treatment for a range of psychiatric disorders. Following the lead of Aaron Beck, cognitive-behavioral therapy (CBT) researchers elaborated on a psychotherapeutic approach that has roots in psychodynamic theory but is more behavior and symptom focused and psychoeducational in its approach to patients. CBT therapists have led the way in developing psychotherapies that could be outlined in a manual and that are amenable to randomized controlled trials. In addition, they have demonstrated that CBT is superior to placebo and/or equivalent to the use of medications for a range of disorders,3 including mood, anxiety, and personality disorders. Through imaging studies, CBT researchers have also demonstrated that effective CBT treatment leads to brain change. For example, CBT responders can be distinguished from CBT nonresponders in the treatment of obsessive-compulsive disorder on the basis of brain change.4
More recently, psychodynamic psychotherapy researchers have also been able to demonstrate evidence of change using empirical research designs. Milrod and colleagues5 showed that psychodynamic therapy is effective in treating panic disorder, while Chiesa and Fonagy6 demonstrated that psychodynamic therapy is effective in personality disorders. Similarly, Clarkin and colleagues7 provided promising evidence that their manualized psychodynamic therapy called "transference focused psychotherapy" is beneficial in the treatment of suicidal patients with borderline personality disorder.
A number of studies have suggested that the combination of medication and psychotherapy is superior to either alone, and several suggest that the provision of both treatment modalities by a psychiatrist is actually less expensive than split treatment.8,9
As the effectiveness of biologic treatments has been scrutinized, there has been increasing recognition of problems posed by treatment-resistant disorders. Studies suggest that 15% to 50% of patients with major depressive episodes have treatment-refractory illness,10,11 and that only a minority recover fully with psychopharmacology.12 The addition of psychotherapy to psychopharmacology may be effective for some patients with treatmentrefractory mood disorders comorbid with personality disorders.11,13
For full article, please visit: